Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (May 2017)
24 slides from Artelo Biosciences's investor presentation, May 16, 2017
Slide 1: Investor Presentation
Artelo BIOSCIENCES www.artalobio.com jone: . E-mail: peter@artolobio.com Investor Presentation May 11812, 2017
Slide 2: Disclaimer
Artelo Disclaimer Biosciences Statements in this Artelo Biosciences presentation that are not historical facts are “forward-looking statements" subject to risks/uncertainties. Such statements are based on current facts/analyses and other information that are based on forecasts of results, estimates
Slide 3: Company
Company
Slide 4: Introduction
Artelo Introduction Biosciences Company: Public quoted in the US Science: Endocannabinoid system modulation Focus: Cannabinoid-based treatments Therapeutic areas: Pain, inflammation, Gl, Cardiovascular, Stroke, Cancer Financing: Bridge to planned larger financing in Q4°17 Stock symbol: ARTL Liabilit
Slide 5: Highlights
Highlights Lead research program is a proprietary drug combination aimed to produce a synergy ith cannabidiol (CBD) Developing our own proprietary compounds with existing partnerships and new research collaborations Supply Agreement secures ‘GMP quality cannabinoid material for non-clinical and clin
Slide 6: Leadership
Leadership
Slide 7: Management Team
Artelo Management Team Bioscrences Gregory Gorgas, President & CEO (Over 30 years of high-impact commercial and development experience as biotech veteran and entrepreneur, including global marketing leadership of Biogen’s worldwide cancer business, commercial officer at Mast Therapeutics with orphan
Slide 8: Board of Directors
Artelo Board of Directors Bioscrences Connie Matsui, Board Chair Serves on multiple pharmaceutical and nonprofit boards bringing executive leadership and general management expertise to her responsibilities. Chaired collaboration for the late stage development and commercialization of rituximab (Mab
Slide 9: Scientific Advisors
Artelo Scientific Advisors Bioscrences Professor Saoirse O'Sullivan, PhD (University of Nottingham) Researcher in development of cannabinoids for cancer, stroke, inflammation, and pain. Over 26 original research articles, 6 reviews and 3 book chapters on the topic of cannabinoid pharmacology. Named
Slide 10: The Science
The Science
Slide 11: What are Cannabinoids?
What are Cannabinoids? Artelo BIoscIENCES Cannabinoids refers to a group of substances that are structurally related to chemicals derived from the cannabis plant or that bind to cannabinoid receptors Types of cannabinoids: = endogenous (endocannabinoid) = derived from the cannabis plant (phytocannab
Slide 12: What is Cannabidiol (CBD)?
What is Cannabidiol (CBD)? Artelo - Second most abundant chemical found in the flowering bud of the cannabis plant + Does not cause the same psychotropic effects as THC ee ee ne ren anti-inflammatory = anti-oxidant + anxiolytic 7 = analgesic © @ anti-epileptic fn = + anti-tumoral = neuroprotectant =
Slide 13: Therapeutic Potential of CBD
Therapeutic Potential of CBD Artelo Beyond current clinical use in multiple sclerosis and epilepsy, non-clinical evidence supports CBD’s potential for multiple therapeutic applications: = Inducing tumour-cell specific cell death in vitro and in vivo in breast, lung and colon cancer, limiting cancer
Slide 14: Industry Sector
Industry Sector
Slide 15: Medical Cannabis Industry
Artelo Medical Cannabis Industry Biosciences ‘The global medical marijuana market size was valued at $11.4 billion in 2015 and is projected to grow with CAGR of 17.1% according to Grand View Research Medical Marijuana Industry Report. U.S. medical marijuana market by application, 2013 - 2025 (USD Bi
Slide 16: Cannabidiol (CBD) Market Advantages
Cannabidiol (CBD) Market Advantages Artelo + According to Forbes, the CBD market will grow to a $2.1 billion market in consumer sales by 2020. + Market rose from barely noticeable a few years ago to $90 million in consumer sales for CBD products in 2015. The CBD market grew 27% to reach $115 million
Slide 17: Biopharma Cannabis Segment
Biopharma Cannabis Segment Artelo CBD science is extensive with first-to-market potential available. Over the last two years there as been renewed interest and investment momentum yet large pharma still watches from sidelines. ‘The biotech cannabis ‘sector has attracted the most funding out ofall th
Slide 18: Sector Leaders
Artelo Sector Leaders Bioscrences Market Capitalization ‘OWC Pharmaceuticals Research Corp (OWCP) Scares: Company websites ae pres reeanes. a5 of ay 8, 2017 18
Slide 19: Opportunity
Opportunity
Slide 20: Research Focus
Research Focus Platform Interests: = Novel and proprietary CBD drug combinations = CBD combined with other cannabinoids = CBD administration via a patentable delivery method = Other product candidates designed to modulate the endocannabinoid system Artelo Bioscrences Therapeutic Interests: Cardiovas
Slide 21: Lead Development Program
Artelo Lead Development Program Biosciences Our lead research program is based upon a proprietary combination product strategy to produce a synergy with CBD hd U = Worldwide, exclusive rights to intellectual property covering the combination product candidate = Patent-perfecting research and formula
Slide 22: Capital - Up to $1,000,000 Raise
Artelo Capital - Up to $1,000,000 Raise BiosclENces Capital expected to fund the next few months and to prepare for a $5-10M equity raise Artolo Biosciences stock symbol: ARTL Common Shares Issued & Outstanding: 9,800,000 Currant Pre-Money Valuation: $4,000,000 USD based on $1M raise at $0.40 per sh
Slide 23: Summary
Summary Public US biopharmaceutical company with offices in Dublin and San Diego Lead program for orphan dise with expansion to more common disorders Building a broad range of development programs and intellectual property portfolio 2B
Slide 24: BIOSCIENCES Fitewilliam Street Upper
Artelo BIOSCIENCES 29 Fitewilliam Street Upper Dublin 2, Ireland www.artelobio.com Greg Gorgas (USA) 760.473.9803 gorgas@artelobio.com Peter O’Brien (IRE) 083 140 6837 ——
Artelo Biosciences — Investor Presentation (May 2017) on 6ix